Featured Research

from universities, journals, and other organizations

Cisplatin Is More Effective Than Carboplatin For Treating Nonsmall Cell Lung Cancer

Date:
June 6, 2007
Source:
Journal of the National Cancer Institute
Summary:
Some patients with advanced nonsmall cell lung cancer have slightly higher survival rates when treated with the chemotherapy drug cisplatin than another platinum-based drug, carboplatin, according to a new study. The authors conclude that cisplatin chemotherapy should remain the standard of care for these patients.

Some patients with advanced non--small-cell lung cancer (NSCLC) have slightly higher survival rates when treated with the chemotherapy drug cisplatin than another platinum-based drug, carboplatin, according to a study in the June 6 Journal of the National Cancer Institute. The authors conclude that cisplatin chemotherapy should remain the standard of care for these patients.

Recent randomized studies have shown that the addition of platinum-based drugs to standard chemotherapy improves patient outcomes. Based on this data, new guidelines for treating advanced NSCLC recommend platinum-based chemotherapy as the standard of care. Most clinicians in North America prefer carboplatin to cisplatin because it has fewer side effects and is easier to administer. Nonetheless, it was unclear whether the drugs are equally effective in NSCLC patients.

Andrea Ardizzoni, M.D., of University Hospital in Parma, Italy, and colleagues conducted a review of nine randomized trials comparing the survival of 2,968 NSCLC patients who received either cisplatin- or carboplatin-based chemotherapy.

Patients who received cisplatin lived slightly longer than those treated with carboplatin, with a median survival of 9.1 months compared with 8.4 months. The difference in survival was not statistically significant, except in patients treated with more recent chemotherapy combinations and those with nonsquamous-cell tumors. Both drugs had side effects. Carboplatin was more likely to decrease blood platelet levels, while cisplatin was more likely to cause nausea, vomiting, and damage to the kidneys.

"Given the palliative nature of chemotherapy treatment in advanced NSCLC and the unquestionable practical advantage of carboplatin in terms of ease of administration, it could be argued that the small benefit achieved with cisplatin relative to carboplatin does not justify its preferential use in clinical practice. However, all the progress in the treatment of advanced NSCLC has been made in small increments," the authors write.

In an accompanying editorial, Christopher Azzoli, M.D., and colleagues at the Memorial Sloan-Kettering Cancer Center in New York discuss the renewed rivalry between cisplatin and carboplatin, particularly in the face of new developments in adjuvant chemotherapy for NSCLC patients. "The apparent superiority of cisplatin over carboplatin demonstrated in this paper should not be taken lightly, particularly in patients being treated with curative intent. Equally inadvisable would be the overzealous use of cisplatin in patients with metastatic NSCLC for whom the drug may be poorly tolerated, such as those with significant baseline renal impairment, hearing loss, peripheral neuropathy, or other serious medical comorbidities," the authors write.

Citations:

Article: Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, et al. Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non -- Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis. J Natl Cancer Inst 2007; 99: 847-857

Editorial: Azzoli CG, Kris MG, Pfister DG. Cisplatin Versus Carboplatin for Patients With Metastatic Non -- Small-Cell Lung Cancer -- An Old Rivalry Renewed. J Natl Cancer Inst 2007; 99: 828-829


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "Cisplatin Is More Effective Than Carboplatin For Treating Nonsmall Cell Lung Cancer." ScienceDaily. ScienceDaily, 6 June 2007. <www.sciencedaily.com/releases/2007/06/070605185731.htm>.
Journal of the National Cancer Institute. (2007, June 6). Cisplatin Is More Effective Than Carboplatin For Treating Nonsmall Cell Lung Cancer. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2007/06/070605185731.htm
Journal of the National Cancer Institute. "Cisplatin Is More Effective Than Carboplatin For Treating Nonsmall Cell Lung Cancer." ScienceDaily. www.sciencedaily.com/releases/2007/06/070605185731.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Beijing Marathon Runners Brave Hazardous Air Pollution

Beijing Marathon Runners Brave Hazardous Air Pollution

AFP (Oct. 19, 2014) Tens of thousands of runners battled thick smog at the Beijing Marathon on Sunday, with some donning masks as the levels of PM2.5 small pollutant particles soared to 16 times the maximum recommended level. Duration: 00:54 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins